Imatinib
- Generic Name
- Imatinib
- Brand Names
- Gleevec, Glivec, Imatinib Teva, Imatinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C29H31N7O
- CAS Number
- 152459-95-5
- Unique Ingredient Identifier
- BKJ8M8G5HI
- Background
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...
- Indication
Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- David Miklos
- Target Recruit Count
- 15
- Registration Number
- NCT00760981
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, United States
Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg
- Conditions
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 94
- Registration Number
- NCT00751036
- Locations
- 🇻🇪
Novartis Investigative Site, Caracas, Distrito Capital, Venezuela
High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)
- Conditions
- First Posted Date
- 2008-06-30
- Last Posted Date
- 2009-02-02
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT00707408
- Locations
- 🇫🇷
Nantes University Hopspital, Nantes, France
Study of Temzolomide and Gleevec in Advanced Melanoma
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 32
- Registration Number
- NCT00667953
- Locations
- 🇺🇸
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States
Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 88
- Registration Number
- NCT00632255
- Locations
- 🇬🇧
Haematology Department. Catherine Lewis Centre. Hammersmith Hospital. Du Cane Road., London, United Kingdom
Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients
- Conditions
- Interventions
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 8
- Registration Number
- NCT00585221
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Safety Study of Gleevec® in Children With Pulmonary Hypertension
- First Posted Date
- 2007-12-31
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 1
- Registration Number
- NCT00583115
- Locations
- 🇺🇸
Indiana University School of Medicine; Riley Hospital for Children, Indianapolis, Indiana, United States
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 502
- Registration Number
- NCT00574873
- Locations
- 🇺🇸
Pacific Cancer Medical Center Inc, Anaheim, California, United States
🇺🇸Robert A Moss, MD, FACP, Inc, Fountain Valley, California, United States
🇺🇸Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2009-09-03
- Lead Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Target Recruit Count
- 30
- Registration Number
- NCT00573326
- Locations
- 🇮🇹
Università Politecnica delle Marche, Ancona, Italy
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
- First Posted Date
- 2007-08-21
- Last Posted Date
- 2011-11-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT00519090
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Southern California Permanente Medical Group, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.